Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Açın
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1.091,51
-2,30
-0,21%
—1.093,811.096,521.100,221.091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1.237,98
-16,83
-1,34%
—1.254,811.253,011.253,871.226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1.744,71
-16,40
-0,93%
—1.761,111.764,271.766,881.744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3.260,69
+48,86
+1,52%
—3.211,833.227,213.268,383.226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1.466,80
-7,72
-0,52%
—1.474,521.479,031.481,041.466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2.397,50
+5,38
+0,22%
—2.392,122.396,952.421,222.382,32——
ATAI:NASDAQ
AtaiBeckley Inc
4,14 US$
-0,60%
(-0,025) 1D
4,11 US$
-0,58% (-0,024)
After hours
Closed: 1 may, 16:00:04 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATAI...
Açın
4,15 US$
High
4,20 US$
Low
4,08 US$
Mkt. cap
1,52 mlrd
Avg. vol.
6,58 mln
Volume
2,36 mln
52-wk high
6,72 US$
52-wk low
1,29 US$
EPS
-2,91 US$
Beta
1,57
Shares outstanding
366,92 mln
No. of employees
99
News stories
From sources across the web
Profile
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
About AtaiBeckley Inc
CEOFlorian Brand
Employees99
Founded2018
Headquarters-
SectorPharmaceutical industry
Websiteataibeckley.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
mar 2025
iyn 2025
sen 2025
dek 2025
Revenue
1,56 mln
719,00K
749,00K
1,07 mln
Cost of goods sold
10,84 mln
10,51 mln
14,68 mln
10,91 mln
Cost of revenue
10,84 mln
10,51 mln
14,68 mln
10,91 mln
Research and development expenses
-
582,00K
-
4,00 mln
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,99 mln
14,90 mln
14,50 mln
24,40 mln
Operating expense
9,99 mln
15,48 mln
14,50 mln
28,41 mln
Total operating expenses
20,82 mln
25,99 mln
29,18 mln
39,32 mln
Operating income
-19,27 mln
-25,27 mln
-28,44 mln
-38,25 mln
Other non operating income
-13,01 mln
-6,33 mln
-51,25 mln
13,99 mln
EBT including unusual items
-26,34 mln
-27,68 mln
-61,00 mln
-544,84 mln
EBT excluding unusual items
-32,54 mln
-30,16 mln
-79,20 mln
-23,71 mln
Income tax expense
128,00K
65,00K
102,00K
3,00K
Effective tax rate
-0,49%
-0,23%
-0,17%
-
Other operating expenses
-
-
-
-
Net income
-26,43 mln
-27,73 mln
-61,07 mln
-544,81 mln
Net profit margin
-1.699,74%
-3.856,61%
-8.154,07%
-51.108,16%
Earnings per share
-0,15
-0,14
-0,28
-1,73
Interest and investment income
186,00K
248,00K
504,00K
542,00K
Interest expense
-900,00K
-264,00K
-
-
Net interest expenses
-714,00K
-16,00K
504,00K
542,00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-19,05 mln
-25,05 mln
-28,20 mln
-37,91 mln
Gain or loss from assets sale
-
-
-
692,00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer